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Abstract Osteoporosis, which is a systemic skeletal disease
characterized by low bonemineral density andmicroarchitectural
deterioration of bone quality, is a global and increasing public
health problem. Recent studies have suggested that Tenuigenin
(TEN), a class of native compounds with numerous biological
activities such as anti-resorptive properties, exerts protective ef-
fects against postmenopausal bone loss. The present study aims
to investigate the osteogenic effects of TEN on bone mesenchy-
mal stem cells (BMSCs) in vitro and in vivo. Alkaline phospha-
tase (ALP) activity/staining, Alizarin red staining and the expres-
sion of osteogenic markers, including runt-related transcription
factor 2, osterix, osteocalcin, collagen Iα1, β-catenin and glyco-
gen synthase kinase-3β were investigated in primary femoral
BMSCs from C57/BL6 mice cultured under osteogenic condi-
tions for 2 weeks to examine the effects of TEN. An ovariecto-
mized (OVX) mouse model was used to investigate the effect of
TEN treatment for 3months in vivo.We found that ALP activity,
mineralized nodules and the expression of osteogenic markers
were increased and WNT/β-catenin signaling was enhanced
in vitro and in vivo. Bone parameters, including trabecular thick-
ness, trabecular number and bone mineral density were higher in
the OVX+TEN group than in control OVX mice. Our results
suggest the therapeutic potential of TEN for the treatment of
patients with postmenopausal osteoporosis.
Keywords Osteoporosis . Tenuigenin . BMSCs . Bone
parameters .WNT/β-catenin signaling
Introduction
Osteoporosis (OP) is a common and systemic skeletal disease
characterized by low bone mineral density (BMD) and
microarchitectural deterioration of bone quality that reduces
bone strength, with a consequent increased risk of fragile frac-
tures (van den Bergh et al. 2012). More than 200 million
people worldwide are affected by osteoporosis, especially
postmenopausal women and older men (Liu et al. 2015; Tao
et al. 2016). Osteoporosis increases the frequency of fractures
of the hip, spine and wrist in association with substantial
morbidity and mortality and the direct costs of osteoporotic
treatments appear to be rising dramatically concomitant with
the increase in life expectancy (Li et al. 2016). Although hor-
mone replacement therapy is the most common therapeutic
approach for the prevention and treatment of postmenopausal
osteoporosis, the Women’s Health Initiative reported that the
health risks of hormone replacement therapy exceed its bene-
fits (Yu et al. 2016). The use of bisphosphonates for the treat-
ment of osteoporosis has also been reported (Bagan et al.
2016; Eriksen et al. 2014; Safer et al. 2016). However, the
potential bone-forming agents in bisphosphonates are associ-
ated with serious side effects and may not yield the expected
improvements in bone quality and bone union ratio (Luhe
et al. 2008). Furthermore, the cost-effectiveness of their wide-
spread or long-term use has been questioned. Despite the
availability of an armamentarium of agents, finding the
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optimal agent remains a challenge (Demontiero et al. 2012).
Therefore, it is desirable to identify better and safe anabolic
agents for the treatment of osteoporosis.
Bone mass is controlled by continuous bone remodeling
through osteoblastic bone formation and osteoclastic bone re-
sorption. Abnormalities in bone remodeling can produce a
variety of bone-decreasing disorders such as osteoporosis
(Rodan and Martin 2000). During bone remodeling, the re-
moval of old bone from the skeleton is performed by osteo-
clasts, which are derived from hematopoietic stem cells and
the addition of new bone occurs through differentiation/
mineralization by osteoblasts, which are derived from mesen-
chymal stem cells (Boyle et al. 2003; Harada and Rodan
2003). If the balance between bone formation and bone re-
sorption is disturbed and the rate of bone formation is lower
than that of bone resorption, adult skeletal diseases can result
in osteoporosis.
Bone mesenchymal stem cells (BMSCs) are composed of
progenitor and multipotent skeletal stem cells and can differ-
entiate into osteoblasts, osteocytes, adipocytes and chondro
cytes in vitro (Ma et al. 2015). At present, it is understood that
all osteoblasts are derived from BMSCs (Zhang et al. 2016).
As BMSCs can differentiate into skeletal cell phenotypes
(Bianco et al. 2006), they are the most promising and thor-
oughly investigated population of stem cells in osteoporosis
research.
Tenuigenin (TEN), the chemical structure of which has
been elucidated, is the active component of the root of the
Chinese herb Polygala tenuifolia. It has a variety of biological
activities, including anti-apoptotic, anti-oxidative and anti-
inflammatory effects (Liang et al. 2011; Sun et al. 2007). A
recent report suggested that TEN is a potential drug for the
treatment of osteoporosis by suppressing osteoclastogenesis
(Yang et al. 2015). Osteoblast differentiation and osteoclasto-
genesis are two important phases of bone remodeling; how-
ever, whether TEN affects the osteogenic differentiation of
BMSCs in vitro and bone formation in vivo remains
unknown.
In the present study, we investigate the osteogenic activity
of TEN and its underlying mechanism in vitro and in vivo.
Our results indicate that TEN induces the differentiation of




TEN (Fig. 1a) was obtained from Sigma–Aldrich (St Louis,
MO, USA). A stock solution of TEN (10mg/ml) was prepared
in dimethyl sulfoxide (DMSO; Sigma–Aldrich) and stored at
2–8 °C. TEN stock was diluted in sterile phosphate-buffered
saline (PBS) and PBS-DMSO (0.16 %) served as the control
in cell culture experiments.
Animals and drug treatment
A total of 30 female C57BL/6 mice aged 8 weeks and
weighing 22 ± 3 g were provided by the Southern Medical
University (Guangzhou, Guangdong, People’s Republic of
China). The mice were assigned equally to each of three
groups: sham, ovariectomized (OVX) and OVX+TEN.
OVX+TENmice received TEN (6mg/kg/day) intragastrically
every day for 3 months after ovariectomy. The sham and OVX
groups received the same amount of normal saline. Ethical
approval for this study was obtained from the Medical
Ethics Committee of the Southern Medical University
(2015-095). The mice were kept following the animal care
guidelines of the Southern Medical University laboratory
animal welfare and ethics committee charter.
Cell culture and osteogenic differentiation
BMSCs were isolated from C57BL/6 mice (aged 4 weeks).
Briefly, mice femurs were dissected free of surrounding
soft tissue. The bone marrow was flushed with α-MEM
(Gibco, Grand Island, NY, USA). The marrow content
from four to six bones was plated in culture flasks con-
taining BMSC growth media (α-MEM containing 10 %
fetal bovine serum, 100 U/ml penicillin,100 mg/ml strep-
tomycin sulfate; Sigma-Aldrich). Non-adherent cells were
removed and adherent BMSCs were cultured and expand-
ed for further experiments. Primary cells were used in the
experiments prior to the third passage. Cell culture media
were replaced every 3 days.
Cell proliferation assay
Primary BMSCs were seeded in 96-well plates at a density of
3.13 × 104 cells/cm2. After 2 days in culture, cells were treated
with TEN at concentrations of 4, 8, 16 and 32 μg/ml for
14 days. Cell proliferation was assessed using the Cell
Counting Kit-8 (CCK-8; Keygen Biotech, Nanjing, People’s
Republic of China) colorimetric assay according to the man-
ufacturer’s instructions. Absorbance was measured at 450 nm.
ALP activity/staining assay
Cells were plated into six-well plates at a density of
2.08 × 104 cells/cm2. Following treatment with TEN
(4–16 μg/ml) and osteoblast differentiation for 14 days,
the cells were washed twice with PBS, scraped into
500 μL of 10 mM Tris-HCl buffer (pH 7.6) containing
0.1 % Triton X-100, placed on ice and sonicated to
lyse the cells. Protein concentrations in the lysates were
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determined using the Bradford protein assay. Alkaline
phosphatase (ALP) activity in the cellular fraction was
measured using a fluorometric detection kit (Nanjing
Jiancheng Biotechnology, Nanjing, People’s Republic
of China). A standard curve was created using p-nitro-
phenol as the standard and the ALP activity of each
sample was calculated from optical density (450 nm)
values. Parallel wells were stained for ALP. Cells were
fixed in 4 % paraformaldehyde (Sigma-Aldrich) for
20 min at room temperature, washed, incubated with
ALP staining buffer (NBT-BCIP; Sigma-Aldrich) at
37 °C for 30 min and washed with PBS to remove
excess dye.
Alizarin red assay
BMSCs (2.08 × 104 cells/cm2) were plated and cultured
in six-well plates with various concentrations of TEN
(4–16 μg/ml) in osteogenic medium for 14 days. On
day 14, the Alizarin red assay (Sigma-Aldrich) was per-
formed to determine mineralization. Briefly, cells were
washed with PBS and fixed with 4 % paraformaldehyde
for 30 min at room temperature. Fixed cultures were
incubated with 1 % Alizarin red for 30 min and
washed with PBS to remove excess dye. Extracellular
matrix mineral-bound stain was photographed under a
microscope. For quantification, the bound staining was
eluted with 10 % (wt/vol) cetylpyridinium chloride
(Sigma-Aldrich) and the absorbance of the supernatants
was measured using an automated microplate reader
(Bio-Rad, Hercules, CA, USA) at 570 nm.
Quantitative reverse transcription PCR (qRT-PCR) assay
Total RNAwas isolated from BMSCs with the TRIzol reagent
(Life Technologies, Grand Island, NY, USA) according to the
manufacturer’s instructions after 2 weeks of osteogenic induc-
tion. Total RNA products were immediately converted to
cDNA by reverse transcription (RT) using a PrimeScript RT
reagent Kit with gDNA Eraser (TaKaRa, Dalian, China).
Polymerase chain reaction (PCR) amplification was per-
formed in a Chromo4 Four-Color Real-Time PCR Detection
System (Bio-Rad) using a SYBRR Premix Ex Taq II (Tli
RNaseH Plus) kit (TaKaRa). Primer sequences (Life
Technologies) for each gene used in this study are shown in
Table 1.
Western blot (WB) assay
Proteins isolated from six-well plates were subjected to
SDS-polyacrylamide gel electrophoresis and transferred
to polyvinylidene (PVDF) membranes (Sigma-Aldrich).
Membranes were probed with rabbit polyclonal antibod-
ies to runt-related transcription factor 2 (Runx2) (Cell
Signaling Technology, Danvers, MA, USA), osterix
(OSX) (Cell Signaling Technology), osteocalcin (OCN)
(Santa Cruz Biotechnology, Santa Cruz, CA, USA), β-
actin (Santa Cruz Biotechnology), β-catenin (Santa Cruz
Biotechnology), glycogen synthase kinase-3β (GSK-3β)
(Santa Cruz Biotechnology) and goat anti-rabbit second-
ary antibody (Santa Cruz Biotechnology). PVDF
membranes were incubated with primary antibodies for
8 h at 4 °C and washed three times with TRIS-buffered
Fig. 1 TEN increased osteogenesis in BMSCs. a Structure of TEN. b
BMSCs was treated with various concentrations of TEN (4, 8, 16 μg/ml)
for 14 days and cell viability was measured by using the CCK-8 assay.
BMSCs were incubated with TEN (4, 8, 16 μg/ml) in osteogenic
differentiation medium for 14 days, then ALP activity (c), mineralized
nodules (d), ALP staining (e–e^’), and Alizarin red staining (f-–f^’) were
tested. +P < 0.05 versus group without TEN, #P < 0.05 compared with
4μg/ml TEN, *P < 0.05 comparedwith 8 μg/ml TEN.Columns represent
means ± SD from 3 independent experiments, each performed in triplicate
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saline with Triton X-100 (TBST; 5 min per wash). The
secondary antibody was incubated with the membranes
for 1 h at room temperature, followed by three washes
with TBST (5 min per wash). Signals were revealed
using an enhanced chemiluminescence kit (Cell
Signaling Technology).
Immunofluorescence staining
Cells were seeded into six-well plates containing glass
cover slides at a density of 2.08 × 104 cells/cm2 and
grown to 95 % confluence. The cells received osteoblast
differentiation medium containing TEN for 2 weeks.
Following fixation in 4 % paraformaldehyde at room
temperature for 30 min, the cells were washed three
times with PBST (0.1 % Triton X-100 in PBS) and
blocked in PBS-bovine serum albumin (1 % bovine se-
rum albumin in PBS) for 1 h at room temperature. Cells
were incubated with antibodies against collagen Iα1
(Col Iα1) (Abcam, Cambridge, MA, USA) for 1 h at
room temperature. The samples were then washed three
times in PBS for 10 min each and incubated with anti-
rabbit immunoglobulin G (H+L), F(ab’) 2 Fragment
Alexa Fluor 594 conjugated secondary antibodies (Cell
Signaling Technology) for 1 h at room temperature. For
nuclear staining, cells were counterstained with 4’,6-
diamidino-2 phenylindole (DAPI, Cell Signaling
Technology) for 5 min. Cells were examined using a
laser confocal microscope (FV1000; Olympus Optical,
Tokyo, Japan). Positive cells were evaluated using
Image-Pro Plus sof tware (Media Cyberne t ics ,
Rockville, MD, USA) to measure cellular fluorescence
intensity. Cells with a fluorescence intensity ≥150 % of
background were considered positive.
Histological and immunohistochemical assay
Femur tissues dissected from the mice were fixed using 4 %
paraformaldehyde in PBS at 4 °C for 24 h and then decalcified
in 15 % ethylenediaminetetra-acetic acid (pH 7.2) at 4 °C for
14 days. The tissues were embedded in paraffin or optimal
cutting temperature compound (Sakura Finetek) and sec-
tioned at 2–5 μm. For histological analysis, the samples were
stained with hematoxylin and eosin (HE) (Sigma-Aldrich).
For immunohistochemistry, the sections were deparaffinized
and briefly washed with PBS. This step was followed by in-
cubation for 30 min in 3 % H2O2 to quench endogenous per-
oxidase activity. Appropriate primary antibodies anti-Runx2
(Cell Signaling Technology), anti-OSX (Cell Signaling
Technology) and anti-OCN (Santa Cruz Biotechnology) were
then applied overnight at 4 °C. After incubation with the pri-
mary antibody, sections were washed three times with PBS
and incubated with goat-anti-mouse horseradish peroxidase-
conjugated secondary antibodies (Cell Signaling Technology)
for 1 h at room temperature. Immunostained sections were
then incubated with DAB. Finally, the sections were
dehydrated, mounted with coverslips and examined using
an Olympus light microscope.
X-ray micro CT assay
Long bones were collected from the mice, dissected free of
soft tissue, fixed overnight in 4 % paraformaldehyde and
analyzed by high-resolution micro-computed tomography
(μCT 80; Scanco Medical , Brut t ise l len, Zurich,
Switzerland). We set the scanner at a voltage of 89 kV, a
current of 112 μA and a scan thickness of 20 μm. Cross-
sectional images of the proximal tibiae and femora were ac-
quired to perform three-dimensional histomorphometric
Table 1 Primer sequences used
in RT-PCR and qPCR Target gene GenBank accession no. Sequences (5’–3’)
GAPDH NM_017008.4 Forward, CAGGGCTGCCTTCTCTTGTG
Reverse, GATGGTGATGGGTTTCCCGT
RUNX2 NM_001145920.2 Forward, AATTAACGCCAGTCGGAGCA
Reverse, CACTTCTCGGTCTGACGACG
OSX NM_001037632.1 Forward, GCCTACTTACCCGTCTGACTTT
Reverse, GCCCACTATTGCCAACTGC
OCN NM_001037939.2 Forward, TCTATGACCTGCAGAGGGCT
reverse,ATAGCTCGTCACAAGCAGGG;
Col1α1 NM_000088.3 Forward, AGTGGTTTGGATGGTGCCAA
Reverse, GCACCATCATTTCCACGAGC
β-catenin XM_006511927.1 Forward, CTGCAACGACCTGACTGGTA
Reverse, GGCCATGTCCAACTCCATCA
GSK-3β XM_006522425.1 Forward, AGAAGAGCCATCATGTCGGG
Reverse, CCAAAAGCTGAAGGCTGCTG
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analyses of the trabecular bone. The analyses included various
bone parameters, including trabecular thickness, trabecular
number and trabecular BMD.
Statistical analysis
Data are representative of at least three independent experi-
ments. Each experiment was performed in triplicate. Data
were graphed using GraphPad Prism software v.3.0. One-
way analysis of variance followed by the Student’s t test was
used to determine statistical differences. Error bars represent
the standard error of the mean in the cell experiments and the
standard deviation in the animal experiments.
Results
TEN has no toxic effects on the proliferation of BMSCs
Firstly, the toxicity of TEN was measured by the CCK-8 as-
say. BMSCs were treated with different concentrations of
TEN (4-, 8-, 16- and 32 μg/ml) for 14 days. No alteration
of cell viability was observed in BMSCs cultured in the pres-
ence of TEN at concentrations of 4, 8 and 16 μg/ml (Fig. 1b).
The test suggested that TEN is not harmful to the proliferation
of BMSCs at concentrations of 4, 8 and 16 μg/ml.
TEN stimulates osteogenic differentiation of BMSCs
in vitro
To examine the effects of TEN on osteogenic differentiation,
BMSCs were treated with TEN (4, 8 and 16 μg/ml) in osteo-
genic medium for 14 days. Then, ALP activity/staining and
Alizarin red staining were measured and the expression of the
osteogenic markers Runx2, OSX, OCN and Col Iα1 was
determined by qRT-PCR, WB, or immunostaining. TEN in-
creased the expression of ALP (Fig. 1c, e–e^’), while miner-
alized nodules (Fig. 1d) and Alizarin red staining (Fig. 1f–f^’)
were also improved in a dose-dependent manner. The mRNA
expression of Runx2 (Fig. 2a), OSX (Fig. 2b), OCN (Fig. 2c)
and Col Iα1 (Fig. 2d) was upregulated in a dose-dependent
manner, as shown by qRT-PCR. In addition, the protein ex-
pression of Runx2 (Fig. 2e, f), OSX (Fig. 2e, g) and OCN
(Fig. 2e, h) was also increased in a dose-dependent manner.
Immunostaining for Col Iα1 (Fig. 2i–i^’, j) showed a dose-
dependent increase that peaked at 16 μg/ml. These results
suggest that TEN promotes in vitro osteogenesis.
Effect of TEN on femur bone microstructure
morphometrics and histologic appearance
To confirm the effect of ovariectomy, body weight and the
mass of the uterus were recorded. Body weight increased in
the OVX and OVX+TEN groups (Fig. 3d). The mass of the
uterus in the sham group was significantly greater than that in
the OVX group or OVX+TEN group (Fig. 3e). These data
confirm that the excision of the ovaries was successful. To
evaluate the effect of TEN on bone formation in mice, we
performed X-ray μCT analyses of sham, OVX and
OVX+TEN mice. X-ray μCT results for the long bones of
the OVX+TEN mice demonstrated a clear trend in which
trabecular thickness was increased relative to that in the
OVX group (Fig. 3b–b^, c–c^, g). Trabecular number
(Fig. 3b–b^, c–c^, f) and trabecular BMD (Fig. 3b–b^,
c–c^, h) in bones from the OVX+TEN group were significant-
ly higher than those in bones from the OVX group. However,
these parameters were not significantly different between the
OVX and sham groups. HE staining of femoral bone sections
indicated that the number of trabeculae was significantly low-
er in OVX mice than in the OVX+TEN group (Fig. 3a-a^).
TEN promotes the expression of Runx2, OSX and OCN
in vivo
To examine the molecular and cellular changes associated
with TEN-mediated protection against bone loss in vivo, we
examined the epiphyseal growth plate, where bone formation
occurs on a cartilaginous template (Karsenty 2003;
Kronenberg 2003). Expression of Runx2 (Fig. 4a–a^, d),
OSX (Fig. 4b–b^, e) and OCN (Fig. 4c–c^, f) was markedly
lower in OVX mice than in sham and OVX+TEN mice.
However, there were no statistically significant differences
between the sham group and the OVX+TEN group. Our
in vitro and in vivo data indicate that TEN-induced osteogen-
esis positively regulates bone formation.
Effect of TEN on WNT/β-catenin signaling
To gain further insight into the function of TEN in the osteo-
genic differentiation of cultured BMSCs, we examined the
mRNA expression of β-catenin and GSK-3β in vitro. Our
qRT-PCR results showed that β-catenin (Fig. 5a) and GSK-
3β (Fig. 5b) expression was enhanced. In addition, we inves-
tigated the β-catenin (Fig. 5c, d) and GSK-3β (Fig. 5c, e)
protein levels, which were both increased in BMSCs after
TEN treatment. Collectively, these data indicate that WNT/
β-catenin signaling is increased in BMSCs in the presence
of TEN and suggest that TEN cooperates with WNT/β-
catenin signaling to regulate bone formation.
Discussion
TEN is the active component of the Chinese herb Polygala
tenuifolia root that has no genotoxic effects and is safe at the
proper dose (Shin et al. 2015). It has been suggested as a
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potential drug for the treatment of osteoporosis (Yang et al.
2015). TEN also belongs to the family of saponin compounds,
including ginsenoside, asperosaponin VI, diosgenin and
platycodon, which inhibit osteoclastogenesis and stimulate
osteoblast differentiation (Folwarczna et al. 2016; Gu et al.
2016; Jeong et al. 2010; Niu et al. 2011). Based on the report-
ed effect of TEN on the inhibition of osteoclastogenesis, we
explored its effect on BMSC osteogenic differentiation and
bone formation. The results of the present study showed that
TEN promoted osteoblast differentiation, which is similar to
data obtained with other saponin compounds. These results
suggest that TEN could be a novel compound for the
modulation of osteoblast differentiation and indicate a need
for continued study of TEN as a potential therapeutic agent for
Fig. 2 Effect of TEN on osteogenic markers in vitro. BMSCs were
cultured in osteogenic medium and exposed to TEN (4, 8, 16 μg/ml)
for 14 days. Total cytosolic RNA was prepared and used for
quantitative RT polymerase chain reaction analysis of Runx2 (a), OSX
(b), OCN (c) and Col Iα1 (d) as described in BMaterials and methods^.
Cell lysates (20 μg) were obtained for western blot and analyzed using
antibodies specific for Runx2 (e, f), OSX (e, g) and OCN (e, h). The
expression of Col Iα1 was assessed by immunofluorescence
staining (i–i^’, j). Scale bar 5 μm. Columns represent means ± SD from
3 independent experiments, each performed in triplicate
Fig. 3 TEN prevents bone loss in OVXmice. a–a^HE staining of femur
sections was assessed after 3 months of treatment. b–b^, c–c^ The femurs
were scanned with a high-resolution X-ray micro-CT and the
microstructural indices were performed with the micro-CT data as
described in BMaterials and methods^, including trabecular number (f),
trabecular thickness (g) and trabecular BMD (h). Body weight (d) and
uterine weight (e) were also performed to confirm the effect of the ovarian
excision. Scale bars (a–a^) 50 μm, (b–b^) 1 mm, (c–c^) 100 μm. Data
are shown as mean ± SD from at least three independent experiments,
*P < 0.05
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bone disorders, since it is expected to not only enhance bone
formation but also suppress bone resorption.
Osteogenic differentiation is a complex process that in-
volves a large number of regulators such as ALP, Ruxn2,
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OSX, OCN and Col Iα1 (Xu et al. 2012; Yonezawa et al.
2011). ALP, a cell membrane-associated enzyme, appears
early during the differentiation of osteoblasts and is the
most widely recognized marker of osteoblastic differenti-
ation (Zou et al. 2008; Serigano et al. 2010). ALP activity
correlates with matrix formation in osteoblasts prior to the
initiation of mineralization (Ying et al. 2013). Runx2 and
OSX are the primary regulators of osteogenic differentia-
tion and modulate the expression of other bone markers
(Lee et al. 2008). OCN is involved in controlling the
mineralization process; it appears at a late stage of osteo-
genic differentiation and is expressed in mature cells of
the osteoblastic lineage (Sun et al. 2010; Hauschka et al.
1989). Col Iα1, an important component of the bone ex-
tracellular matrix, connects the cell surface integrins with
other extracellular matrix proteins (Lian and Stein 1992).
In the present study, TEN effectively upregulated ALP,
Runx2, OSX, OCN and Col Iα1, thereby enhancing
Fig. 4 Effect of TEN on the
expression of Runx2, OSX and
OCN in vivo. Weak positive
staining for Runx2 (a–a^, d),
OSX (b–b^, e) and OCN (c–c^, f)
was observed, especially on the
surface of bone lacuna in the
OVX group after 3 months. Scale
bars (a–a^), (b–b^), (c–c^)
20 μm.Columns represent means
± SD from at least three
independent experiments,
*P < 0.05
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mineralization. TEN promoted the osteogenic differentia-
tion and maturation of BMSCs, suggesting that TEN is
effective in preventing osteoporosis by promoting
BMSC function.
To investigate the effects of TEN on postmenopausal
osteoporosis in vivo, we used the OVX mice model
(Spilmont et al. 2013). Our data showed that TEN signifi-
cantly improved the trabecular bone microarchitecture of
the distal femur in OVX mice. This suggests that TEN is
effective in preventing OVX-induced bone loss. These find-
ings were confirmed by histological examination of femur
tissues using HE staining and by assessing the expression
of Runx2, OSX and OCN in femurs. Consistent with the
in vitro results, TEN upregulated osteogenic markers
in vivo, indicating that TEN stimulates bone formation
and growth. Taken together, our in vitro and in vivo results
show that TEN not only promoted osteogenic differentia-
tion in the early stage but also in the late stage of the
osteogenic process, which is similar to the effects of other
saponin compounds such as ginsenoside, asperosaponin VI,
diosgenin and platycodon.
Several studies have reported that osteoporosis in
postmenopausal women is often accompanied by depres-
sion, neurasthenia and hypomnesis (Gonzalez-Rodriguez
et al. 2016; Heuser and Staemmler 1973; Hickey et al.
2016). TEN has been shown to ameliorate learning and
memory impairments induced by ovariectomy (Cai et al.
2013). As TEN has anti-aging, anti-depressant, neuro-
protective and neuroregene rative effects, it may be
more effective than other saponin compounds. TEN is
suitable for the treatment of women with osteoporosis
associated with depression, neurasthenia, hypomnesis,
memory impairments and many other degenerative
diseases.
WNT/β-catenin signaling, which is a crucial signal
pathway, has sparked great interest in recent decades
for its essential role in regulating bone biology and
disease (Gu et al. 2015; Manolagas 2014; Tao et al.
2016). A previous study reported that WNT signaling
can directly suppress the commitment of MSCs to
chondrogenic and adipogenic lineages and enhance os-
teogenic differentiation via both β-catenin-dependent
and β-catenin-independent mechanisms (Hill et al.
2005). Moreover, the expression of the markers of
Fig. 5 Effect of TEN on WNT/β-catenin signaling. BMSCs were cul-
tured in osteogenic differentiation medium with the treatment of TEN (4,
8, 16 ug/ml) for 14 days. The mRNA expression of β-catenin (a) and
GSK-3β (b) was measured by Q-PCR. The protein expression of β-
catenin (c, d) and GSK-3β (c, e) was assessed by western blot.
+P < 0.05 veruss group without TEN, #P < 0.05 compared with 4 μg/ml
TEN, *P < 0.05 comparedwith 8μg/ml TEN.Columns represent mean ±
SD from 3 independent experiments, each performed in triplicate
Fig. 6 TEN promotes differentiation of BMSCs into osteoblasts. The
maturation and survival of osteoblasts are supported by WNT canonical
signaling, resulting in the enhancement of Runx2, OSX and OCN
Cell Tissue Res (2017) 367:257–267 265
mature osteoblasts ALP, OSX, Col Iα1, Runx2 and
OCN in osteoblasts can be increased by activation of
the WNT/β-catenin pathway (Frey et al. 2015; Hwang
et al. 2015; Li et al. 2015). To gain further insight into
TEN-induced osteogenic differentiation, we investigated
the expression of β-catenin and GSK3β, which are key
factors in WNT signaling that regulate bone formation
(Rossini et al. 2013). Our results showed that β-catenin
and GSK3β were upregulated by TEN, suggesting that
TEN stimulates BMSC osteogenic differentiation by ac-
tivating WNT signaling.
The present study had several limitations. First, the ef-
fect of TEN on rat BMSCs was examined under osteogenic
differentiation conditions. The effect of TEN on human
BMSCs needs to be examined to substantiate these results.
Second, although our findings indicate a protective effect of
TEN on osteoporotic bone, we did not include a positive
control group, such as estrogen treatment or a control+TEN
group. A control group, control+TEN group and sham+
estrogen group are worthy of further in-depth study.
Third, we only obtained BMSCs from mice because of
ethical reasons. Additional human BMSCs from healthy
persons and osteoporosis patients would be helpful to iden-
tify whether these findings are specific.
In conclusion, our study provides novel insights into the
effects of TEN on BMSC osteogenic differentiation and its
protective effect on bone loss in mice. We demonstrated,
for the first time, that TEN promotes osteogenesis by up-
regulating Runx2, OSX and OCN at the tissue and cellular
levels, thereby promoting the lineage differentiation of
BMSCs into osteoblasts. Furthermore, we have shown that
WNT signaling is at least partly involved as an underlying
mechanism in this process (Fig. 6). In future studies, the
use of TEN for the stimulation of bone formation in post-
menopausal women and the treatment of depression, neur-
asthenia, hypomnesis, memory impairments and many other
degenerative diseases should be examined by performing
pharmacokinetic and toxicological analyses in humans as
well as randomized control studies.
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